This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Her-2/neu T-cell vaccine, Her2/neu T-cell vaccine
Description: Corixa's HER-2/neu is an encapsulated Her-2/neu peptide p369-377 in poly(lactide-co-glycolide) microspheres used as a breast cancer vaccine. This immunotherapy is based upon a cancer antigen that was developed during a vaccine discovery collaboration with GSK.
In May 2005, GSK announced it would acquire Corixa.
GSK 719125 News
Pink Sheet GSK suspends Entereg development
Pink Sheet GSK expands skin care portfolio
Additional information available to subscribers only: